← 홈

방광·요로상피 · HER2

4개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-13 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 153상태 ACTIVE
ADCBiologicRemeGen Co., Ltd.sPhase 2

disitamab vedotin (Disitamab Vedotin, RC48)

Non-Muscle Invasive Bladder Cancer; HER2 · Gastric Cancer/Gastroesophageal Junction

#GastricCancerGastroesophagealJun#ADC#Phase2#인기#항체약물접합체+5
임상시험 56상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE